Citations

Clear

4093 citation(s) found for "Yu, Jonathan".

Identification of Pathological UIP in Patients with an Alternative Diagnosis (to IPF) Pattern using Quantitative CT Analysis
Thirkateh, Prahasit , Montner, Steven M. , Lee, C. , Husain, Aliya N. , Noth, Imre , Strek, Mary E. , Chung, Jonathan Hero , Adegunsoye, Ayodeji , Oldham, Justin M , Bartholmai, Brian J.

Mayo Clinic

C22. ILD: DIAGNOSIS | August 26, 2019 | Volume: No volume available | Issue: No issue available | Pages: A4316-A4316

10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a4316 Get It

Clinical Utility Analysis of the Envisia Genomic Classifier
Flaherty, Kevin R. , Groshong, Steve D. , Larsen, Brandon T. , Gauhar, Umair, Benzaquen, Sadia , Calero, Karel , Hagmeyer, Lars , Neville, Hannah, Pankratz, Daniel G., Choi, Y. , Huang, Jing , Lofaro, Lori , Lynch, David A. , Chung, Jonathan Hero , Lederer, David J. , Kennedy, G., Martínez, Fernando J.

Mayo Clinic

D12. ILD: DIAGNOSIS AND PROGNOSIS | August 26, 2019 | Volume: No volume available | Issue: No issue available | Pages: A5837-A5837

10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a5837 Get It

Articular Cartilage Defects of the Glenohumeral Joint: A Systematic Review of Treatment Options and Outcomes
Fiegen, Anthony P. , Leland, Devin P. , Bernard, Christopher D. , Krych, Aaron J. , Dahm, Diane L., Camp, Christopher L. , Fiegen, Anthony, Barlow, Jonathan D. , Camp, Christopher L. , Krych, Aaron J

Mayo Clinic

CARTILAGE | August 23, 2019 | Volume: 13 | Issue: 1_suppl | Pages: 401S-413S

10.1177/1947603519870858 | PMID 31441316 Get It

Objective To report radiographic and magnetic resonance imaging findings, patient-reported outcomes, and complications and/or reoperations following nonarthroplasty surgical intervention for focal glenohumeral cartilage defects. Design A literature search was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines. Patients were included if they possessed a chondral defect of the humeral head, glenoid, or both, which had been treated with a joint preserving nonarthroplasty procedure. Risk of bias assessment was performed using the Methodological Index for Non-Randomized Studies scoring system. Study demographics, surgical technique, imaging findings, patient-reported outcomes, complications, failures, and reoperations were collected. Results Fourteen studies with 98 patients (100 shoulders) met the inclusion criteria. Patient ages ranged from 7 to 74 years. The nonarthroplasty surgical techniques utilized included microfracture (67 shoulders), osteochondral transplantation (28 shoulders), chondrocyte transplantation (4 shoulders), and internal fixation (1 shoulder). The rates of radiographic union and progression of osteoarthritis ranged between 90% to 100% and 57% to 100%, respectively. Visual analog scores ranged from 0 to 1.9 at final follow-up. Mean postoperative ASES (American Shoulder and Elbow Surgeons) shoulder scores ranged from 75.8-100. Mean postoperative CSS (Constant Shoulder Score) scores ranged from 83.3-94. Mean postoperative SSV (Subjective Shoulder Value) ranged from 70% to 99%. Failure and reoperation rates ranged between 0% to 35% and 0% to 30%, respectively, with the most common reoperation being conversion to prosthetic arthroplasty. Conclusions In this systematic review, nonarthroplasty surgical techniques demonstrated acceptable rates of radiographic healing, improved patient reported outcomes, minimal complications, and low rates of failure or reoperation. Joint preserving techniques are likely viable options to prolong function of the native shoulder and provide short- to midterm pain relief in young and highly active patients. Level of Evidence Level IV.
Identification of Paradoxical Vocal Fold Movement with Diagnostic Ultrasound: Confirmation with Video Laryngoscopy
Finnoff, Jonathan T. , Orbelo, Diana M. , Ekbom, Dale C. , Finnoff, Jonathan T , Orbelo, Diana

Mayo Clinic

PM&R | August 14, 2019 | Volume: 12 | Issue: 4 | Pages: 425-427

10.1002/pmrj.12236 | PMID 31411819 Get It

Genetic overlap between autoimmune diseases and non‐Hodgkin lymphoma subtypes
Din, Lennox, Kosaraju, Nikitha , Smedby, Karin E. , Berndt, Sonja I. , Skibola, Christine F., Nieters, Alexandra, Wang, Sophia , McKay, James , Cocco, Pierluigi , Foretová, Lenka , Staines, Anthony , Mack, Thomas M. , Sanjosé, Sílvia de , Vyse, Timothy J. , Padyukov, Leonid , Monnereau, Alain , Arslan, Alan A. , Moore, Amy , Brooks‐Wilson, Angela , Novak, Anne J. , Glimelius, Bengt , Birmann, Brenda M. , Link, Brian K. , Stewart, Carolyn, Vajdic, Claire M. , Magnani, Corrado , Conti, David V. , Cox, David G. , Casabonne, Delphine, Kane, Eleanor , Roman, Eve , Salles, Gilles , Adami, Hans‐Olov , Ghesquières, Hervé , Vivo, Immaculata De , Clavel, Jacqueline , Spinelli, John J., Curtin, Karen , Costenbader, Karen H. , Onel, Kenan , Offit, Kenneth , Morton, Lindsay M. , Conde, Lucía , Miligi, Lucia , Melbye, Mads , Liebow, Mark , Purdue, Mark P. , Glenn, Martha, Din, M. Azhar Ud, Rothman, Nathaniel , Camp, Nicola J. , Doo, Nicole Wong , Becker, Nikolaus, Pradhan, Nisha , Bracci, Paige M. , Vineis, Paolo , Brennan, Paul , Kraft, Peter , Lan, Qing , Severson, Richard K., Vermeulen, Roel , Kaaks, Rudolph, Travis, Ruth C. , Weinstein, Stephanie J. , Ansell, Stephen M. , Zheng, Tongzhang, Benavente, Yolanda , Taub, Zachary, Madireddy, Lohith, Gourraud, Pierre‐Antoine , Oksenberg, Jorge R. , Hjalgrim, Henrik , Khankhanian, Pouya , Cerhan, James R , Khankhanian, Pouya , Link, Brian K , Cocco, Pierluigi , Brooks-Wilson, Angela R , Vajdic, Claire M , Kane, Eleanor , Arslan, Alan A , Travis, Ruth C , De Vivo, Immaculata , Kraft, Peter , Morton, Lindsay M , Padyukov, Leonid , Salles, Gilles A , Wang, Sophia S , Birmann, Brenda M , Roman, Eve , Clavel, Jacqueline , Conti, David V , Doo, Nicole Wong , Sheikh, Mohammad, Bernatsky, Sasha , Maynadié, Marc , Haïoun, Corinne , Casabonne, Delphine , Albanes, Demetrius , Muzi, Giacomo , Giles, Graham G. , Cerhan, James R. , Hofmann, Jonathan N. , Vijai, Joseph , Teras, Lauren R. , Ennas, Maria Grazia , Southey, Melissa C. , Boffetta, Paolo , Milne, Roger L. , Chanock, Stephen Jacob , Slager, Susan L. , Zhang, Yawei , Cozen, Wendy

Mayo Clinic

Genetic Epidemiology | August 13, 2019 | Volume: 43 | Issue: 7 | Pages: 844-863

10.1002/gepi.22242 | PMID 31407831 Get It

AbstractEpidemiologic studies show an increased risk of non‐Hodgkin lymphoma (NHL) in patients with autoimmune disease (AD), due to a combination of shared environmental factors and/or genetic factors, or a causative cascade: chronic inflammation/antigen‐stimulation in one disease leads to another. Here we assess shared genetic risk in genome‐wide‐association‐studies (GWAS).Secondary analysis of GWAS of NHL subtypes (chronic lymphocytic leukemia, diffuse large B‐cell lymphoma, follicular lymphoma, and marginal zone lymphoma) and ADs (rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis). Shared genetic risk was assessed by (a) description of regional genetic of overlap, (b) polygenic risk score (PRS), (c)"diseasome", (d)meta‐analysis.Descriptive analysis revealed few shared genetic factors between each AD and each NHL subtype. The PRS of ADs were not increased in NHL patients (nor vice versa). In the diseasome, NHLs shared more genetic etiology with ADs than solid cancers (p = .0041). A meta‐analysis (combing AD with NHL) implicated genes of apoptosis and telomere length.This GWAS‐based analysis four NHL subtypes and three ADs revealed few weakly‐associated shared loci, explaining little total risk. This suggests common genetic variation, as assessed by GWAS in these sample sizes, may not be the primary explanation for the link between these ADs and NHLs.
Cost evaluations in health professions education: a systematic review of methods and reporting quality
Foo, Jonathan , Cook, David A. , Walsh, Kieran , Abdalla, Mohamed Elhassan , Ilić, Dragan , Maloney, Stephen , Abdalla, M E , Ilic, Dragan , Maloney, S , Foo, J , Walsh, K , Golub, Robert

Mayo Clinic

Medical Education | August 11, 2019 | Volume: 53 | Issue: 12 | Pages: 1196-1208

10.1111/medu.13936 | PMID 31402515 Get It

Context High‐quality research into education costs can inform better decision making. Improvements to cost research can be guided by information about the research questions, methods and reporting of studies evaluating costs in health professions education (HPE). Our objective was to appraise the overall state of the field and evaluate temporal trends in the methods and reporting quality of cost evaluations in HPE research. Methods We searched the MEDLINE , CINAHL (Cumulative Index to Nursing and Allied Health Literature), EMBASE , Business Source Complete and ERIC (Education Resources Information Centre) databases on 31 July 2017. To evaluate trends over time, we sampled research reports at 5‐year intervals (2001, 2006, 2011 and 2016). All original research studies in HPE that reported a cost outcome were included. The Medical Education Research Study Quality Instrument ( MERSQI ) and the BMJ economic checklist were used to appraise methodological and reporting quality, respectively. Trends in quality over time were analysed. Results A total of 78 studies were included, of which 16 were published in 2001, 15 in 2006, 20 in 2011 and 27 in 2016. The region most commonly represented was the USA ( n = 43). The profession most commonly referred to was that of the physician ( n = 46). The mean ± standard deviation ( SD ) MERSQI score was 10.9 ± 2.6 out of 18, with no significant change over time (p = 0.55). The mean ± SD BMJ score was 13.5 ± 7.1 out of 35, with no significant change over time (p = 0.39). A total of 49 (63%) studies stated a cost‐related research question, 23 (29%) stated the type of cost evaluation used, and 31 (40%) described the method of estimating resource quantities and unit costs. A total of 16 studies compared two or more interventions and reported both cost and learning outcomes. Conclusions The absolute number of cost evaluations in HPE is increasing. However, there are shortcomings in the quality of methodology and reporting, and these are not improving over time.
ALG9 Mutation Carriers Develop Kidney and Liver Cysts
Besse, Whitney , Chang, Alex R. , Luo, Jonathan Z. , Triffo, William , Moore, Bryn S. , Gulati, Ashima , Hartzel, Dustin N. , Mane, Shrikant , Torres, Vicente E. , Somlo, Stefan , Torres, Vicente E , Chang, Alexander R , Mirshahi, Tooraj

Mayo Clinic

Journal of the American Society of Nephrology | August 8, 2019 | Volume: 30 | Issue: 11 | Pages: 2091-2102

10.1681/asn.2019030298 | PMID 31395617 Get It

Significance Statement Dominantly inherited polycystic kidney and liver phenotypes occur when epithelial cells in these organs have reduction of polycystin-1 functional dosage. In a cohort of genetically unresolved polycystic liver and kidney disease, the authors identified heterozygous loss of function mutations in ALG9 . ALG9 encodes an endoplasmic reticulum enzyme that builds N -glycans, and the authors show that Alg9 inactivation results in impaired polycystin-1 maturation. Using a novel ‘genotype-first’ approach to ascertain individuals based strictly on their ALG9 genotype from a large cohort of exome-sequenced individuals, the authors find that 7/8 (88%) of ALG9 mutation carriers over age 50 have multiple kidney cysts. Together, these findings identify ALG9 as a novel human polycystic kidney and liver disease gene and support the utility of a genotype-driven approach to candidate disease gene validation and genotype-phenotype correlation. Background Mutations in PKD1 or PKD2 cause typical autosomal dominant polycystic kidney disease (ADPKD), the most common monogenic kidney disease. Dominantly inherited polycystic kidney and liver diseases on the ADPKD spectrum are also caused by mutations in at least six other genes required for protein biogenesis in the endoplasmic reticulum, the loss of which results in defective production of the PKD1 gene product, the membrane protein polycystin-1 (PC1). Methods We used whole-exome sequencing in a cohort of 122 patients with genetically unresolved clinical diagnosis of ADPKD or polycystic liver disease to identify a candidate gene, ALG9 , and in vitro cell-based assays of PC1 protein maturation to functionally validate it. For further validation, we identified carriers of ALG9 loss-of-function mutations and noncarrier matched controls in a large exome-sequenced population-based cohort and evaluated the occurrence of polycystic phenotypes in both groups. Results Two patients in the clinically defined cohort had rare loss-of-function variants in ALG9 , which encodes a protein required for addition of specific mannose molecules to the assembling N-glycan precursors in the endoplasmic reticulum lumen. In vitro assays showed that inactivation of Alg9 results in impaired maturation and defective glycosylation of PC1. Seven of the eight (88%) cases selected from the population-based cohort based on ALG9 mutation carrier state who had abdominal imaging after age 50; seven (88%) had at least four kidney cysts, compared with none in matched controls without ALG9 mutations. Conclusions ALG9 is a novel disease gene in the genetically heterogeneous ADPKD spectrum. This study supports the utility of phenotype characterization in genetically-defined cohorts to validate novel disease genes, and provide much-needed genotype-phenotype correlations.
Abstract 5113: A flexible pipeline for precision medicine biomarker detection and prediction of treatment response
Hughitt, V. Keith , Gorjifard, Sayeh , Simmons, John K. , Michalowski, Aleksandra M. , Dale, Ryan , Polley, Eric C. , Keats, Jonathan J. , Mock, Beverly A.

Mayo Clinic

Cancer Research | August 7, 2019 | Volume: 79 | Issue: 13_Supplement | Pages: 5113-5113

10.1158/1538-7445.am2019-5113 Get It

Abstract Recent years have seen an explosion in the availability of paired molecular profiling and drug screen data, providing an unprecedented opportunity for the development of targeted therapies based on an individual’s genetic background. Despite a number of recent successes in diseases ranging from cystic fibrosis to cancer, significant hurdles remain in our ability to accurately predict treatments based on molecular profiling data. In particular, few such tools exist that allow the integration of heterogeneous data types (e.g. genomic, transcriptomic, and somatic mutations), along with high-throughput drug screen data to make predictions about treatment efficacy. Here, we describe a generalized open-source pipeline developed for the analysis of precision medicine data, Pharmacogenomics Prediction Pipeline, or “P3”. The modular design of P3 enables the inclusion of arbitrary input data types and the selection from multiple alternative machine learning algorithms, while automated statistical and visualization reporting steps incorporated throughout the pipeline assist in parameter tuning and early detection of problematic data components. Molecular profiling data is further enriched by the incorporation of external biological information in the form of pathway and gene set annotations such and Gene Ontology (GO) and The Molecular Signatures Database (MSigDB). To demonstrate the use of P3 for preclinical biomarker prediction, we applied P3 to an unpublished multiple myeloma dataset consisting of exome, RNA-Seq, CNV, and drug screen data for 1,912 compounds across 47 tumor cell lines. Specifically, P3 was used to predict molecular features associated with response to treatment for all drugs where a differential response to treatment was observed across patients. Furthermore, molecular profiling and drug screen data for 267 drugs and over a thousand cell lines spanning multiple cancer types from the Genomics of Drug Sensitivity in Cancer (GDSC) project were analyzed using P3, providing insights into shared mechanisms of drug sensitivity and resistance across different cancer and treatment types. Citation Format: V Keith Hughitt, Sayeh Gorjifard, Aleksandra M. Michalowski, John K. Simmons, Ryan Dale, Eric C. Polley, Jonathan J. Keats, Beverly A. Mock. A flexible pipeline for precision medicine biomarker detection and prediction of treatment response [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 5113.
Abstract 2686: Associations between a polygenic risk score and risk of multiple myeloma and its precursor
Clay‐Gilmour, Alyssa , Camp, Nicola J. , Brown, Elizabeth E. , Spinelli, John J. , Wu, Xifeng , Robinson, Dennis P. , Kumar, Shaji , Vachon, Celine M. , Hildebrandt, Michelle A.T. , Ziv, Elad , Hofmann, Jonathan N. , Giles, Graham G. , Bhatti, Parveen , Cozen, Wendy , Norman, Aaron D. , Sinnwell, Jason P. , Rajkumar, S. Vincent , Slager, Susan L. , Vachon, Celine M.

Mayo Clinic

Cancer Research | August 7, 2019 | Volume: 79 | Issue: 13_Supplement | Pages: 2686-2686

10.1158/1538-7445.am2019-2686 Get It

Abstract Genome-wide association studies (GWAS) conducted among populations of European ancestry (EA) have identified 23 common single nucleotide polymorphisms (SNPs) associated with multiple myeloma (MM) risk. We hypothesize that the combination of these SNPs in a polygenic risk score (PRS) is likely to be a strong risk factor for MM. However, it is unclear whether the genetic variation associated with MM susceptibility also predisposes to monoclonal gammopathy of undetermined significance (MGUS). Thus, we calculated a PRS and evaluated the association with risk of MM and its precursor, MGUS. We pooled genotype data for 2434 MM and 3446 controls from ten MM GWAS of individuals of EA within the Interlymph Consortium, for 23 MM risk SNPs identified by prior GWAS. An additional 754 MGUS cases were ascertained from Mayo Clinic and MD Anderson clinical practices. To calculate the PRS, we used the risk estimates corresponding to the 23 SNP associations from the largest published MM GWAS. The log of the odds ratio (OR) for each SNP was multiplied by the respective number of risk alleles and summed to generate a PRS for each individual. The PRS was examined continuously, per one standard deviation (SD), and as quintiles, based on the PRS distribution in the controls. Associations of PRS with MM and MGUS risk were examined separately, using multivariable logistic regression assuming an additive model to assess ORs and 95% confidence intervals adjusted for age, sex, and site. We also evaluated age and sex stratified models. The distribution of sex within MM cases, MGUS cases and controls were each ~60% male and ~40% female. The median age was 61, 66, and 66 years for MM cases, MGUS cases and controls, respectively. PRS ranged from 1.52-4.91, with a median PRS of 3.21 for MM cases, 3.19 for MGUS cases, and 3.05 for controls. PRS was significantly associated with MM risk when assessed continuously (OR=1.19 per SD, p=2.2x10-16) and categorically; compared with the middle quintile (Q3), individuals in the highest quintile (Q5) had a 66% increased MM risk (OR=1.66, p=2.3x10-9) and those in the lowest quintile (Q1) had a 38% decreased MM risk (OR=0.62, p=1.3x10-6). PRS was also significantly associated with MGUS risk (OR=1.19 per SD, p=1.7x10-11); individuals with the highest PRS (Q5) had a 77% increased risk (OR=1.77, p=4.0x10-4) and those with lowest PRS (Q1) had 30% decreased risk (OR=0.70, p=0.04), compared with Q3. When stratified by age and sex, similar associations and trends were found. Using an independent sample of MM / MGUS cases and controls, we showed that a PRS constructed from 23 common genetic variants for MM risk is associated with risk of both MM and MGUS, regardless of age or sex. A future direction of this work is testing associations with PRS and clinical characteristics of the MM cases, as well as differences between MGUS cases that progress and those that do not. Our results suggest that common genetic variation may predispose to MGUS as the precursor to MM. Citation Format: Alyssa I. Clay-Gilmour, Michelle A. Hildebrandt, Nicola J. Camp, Elad Ziv, Elizabeth E. Brown, Jonathan N. Hofmann, John J. Spinelli, Graham G. Giles, Parveen Bhatti, Wendy Cozen, Xifeng Wu, Dennis P. Robinson, Aaron D. Norman, Jason P. Sinnwell, Shaji K. Kumar, S Vincent Rajkumar, Susan L. Slager, Celine M. Vachon. Associations between a polygenic risk score and risk of multiple myeloma and its precursor [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 2686.